First Patient Enrolled in the US STEP-1 Clinical Trial of EndoBarrier at Michigan Medicine
January 28, 2020
January 28, 2020
BOSTON, Massachusetts, Jan. 28 -- GI Dynamics issued the following news release:
GI Dynamics(R) Inc. (ASX:GID), a medical device company that is developing EndoBarrier(R) for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan.
Michigan Medicine is one of five clinical study sites for the STEP-1 trial; the site is led by princip . . .
GI Dynamics(R) Inc. (ASX:GID), a medical device company that is developing EndoBarrier(R) for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan.
Michigan Medicine is one of five clinical study sites for the STEP-1 trial; the site is led by princip . . .